Background While clinical factors such as age, grade, stage, and histological subtype
provide physicians with information about patient prognosis, genomic data can further …

Simple Summary This review is a summary of recent findings on the role of prostate-specific
membrane antigen (PSMA) in metastatic castration-resistant prostate cancer (mCRPC) and …

Abstract Purpose of Review Prostate cancer (PrCa) is the most common cancer in men in
the western world and is a major source of morbidity and mortality. Currently, general …

Simple Summary This review paper seeks to summarize the current literature on the role of
PARP Inhibitors in Advanced Prostate Cancer in tumors with defects in genes associated …

Introduction The number of patients with metastatic castration-resistant prostate cancer
(mCRPC) is expected to increase due to the long life expectancy of those with advanced …

Abstract Background Radium (Ra)‐223 is an established treatment option for patients with
metastatic castrate‐resistant prostate cancer (mCRPC) who have symptomatic bone …

Liquid biopsy has emerged as a valuable and minimally invasive tool for real‐time detection
of clinically actionable abnormalities across various cancer types. Its applicability is …

Purpose: We aimed to explore the association between genomic status and clinical outcome
of platinum-based chemotherapy among patients with metastatic castration-resistant …

Molecular-targeted therapies and treatment stratification based on molecular biomarkers
have rapidly gained momentum in the therapeutic spectrum for patients with prostate cancer …

PURPOSE To compare the prevalence of germline mutations in metastatic hormone-
sensitive prostate cancer (mHSPC) and metastatic castrate-resistant prostate cancer …